Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib

Leukemia Research

Volumn 34, Issue 6, 2010, Pages 708-713

  Paquette, Ronald L ^a   Nicoll, John ^a   Chalukya, Meenal ^a   Gondek, Lucas ^b   Jasek, Monika ^b   Sawyers, Charles L ^c   Shah, Neil P ^d   Maciejewski, Jaroslaw ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic myeloid leukemia; Cytogenetics; Dasatinib; Myelodysplastic syndrome; Single nucleotide polymorphism array; TP53

Indexed keywords

DASATINIB; PROTEIN P53;

ADULT; AGED; ARTICLE; CELL POPULATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLONAL VARIATION; CYTOGENETICS; EXON; FEMALE; FRAMESHIFT MUTATION; GENE DELETION; HEMATOPOIESIS; HUMAN; KARYOTYPE; MALE; MONONUCLEAR CELL; MUTATIONAL ANALYSIS; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STOP CODON; UNIPARENTAL DISOMY; X CHROMOSOME INACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BONE MARROW CELLS; CELL DIFFERENTIATION; CLONE CELLS; CYTOGENETIC ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GENES, P53; HEMATOPOIESIS; HUMANS; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHILADELPHIA CHROMOSOME; PYRIMIDINES; THIAZOLES; TREATMENT OUTCOME;

EID: 77952096802     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.08.032     Document Type: Article

References (33)

1. Druker B.J. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008, 112:4808-4817.
2. Deininger M., Buchdunger E., Druker B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005, 2640-2653.
3. Talpaz M., Shah N.P., Kantarjian H., Donato N., Nicoll J., Paquette R., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531-2541.
4. Hochhaus A., Kantarjian H.M., Baccarani M., Lipton J.H., Apperley J.F., Druker B.J., et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007, 109:2303-2309.
5. Medina J., Kantarjian H., Talpaz M., O'Brien S., Garcia-Manero G., Giles F., et al. Chromosome abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003, 98:1905-1911.
6. Bumm T., Müller C., Al-Ali H.K., Krohn K., Shepherd P., Schmidt E., et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood. 2003, 101:1941-1949.
7. O'Dwyer M.E., Gatter K.M., Loriaux M., Druker B.J., Olson S.B., Magenis R.E., et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia. 2003, 17:481-487.
8. McMullin M.F., Humphreys M., Byrne J., Russell N.H., Cuthbert R.J., O'Dwyer M.E. Chromosomal abnormalities in Ph- cells of patients on imatinib. Blood 2003, 102:2700-2701.
9. Terre C., Eclache V., Rousselot P., Imbert M., Charrin C., Gervais C., et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 2004, 18:1340-1346.
10. Loriaux M., Deininger M. Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leuk Lymphoma 2004, 45:2197-2203.
11. Deininger M.W.N., Cortes J., Paquette R., Park B., Hochhaus A., Baccarani M., et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer 2007, 110:1509-1519.
12. Jabbour E., Kantarjian H.M., Abruzzo L.V., O'Brien S., Garcia-Manero G., Vertovstek S., et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2007, 110:2991-2995.
13. Fenaux P., Morel P., Lai J.L. Cytogenetics of myelodysplastic syndromes. Sem Hematol 1996, 33:127-138.
14. Kovitz C., Kantarjian H., Garcia-Manero G., Abruzzo L.V., Cortes J. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 2006, 108:2811-2813.
15. Allen R.C., Zoghbi H.Y., Moseley A.B., Rosenblatt H.M., Belmont J.W. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the androgen-receptor gene correlates with X chromosome inactivation. Am J Human Genet 1992, 51:1229-1239.
16. Delabesse E., Aral S., Kamoun P., Varet B., Turhan A.G. Quantitative non-radioactive clonality analysis of human leukemic cells and progenitors using the human androgen receptor (AR) gene. Leukemia 1995, 9:1578-1582.
17. Maciejewski J.P., Mufti G.J. Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood. 2008, 112:965-974.
18. Mohamedali A., Gaken J., Twine N.A., Ingram W., Westwood N., Lea N.C., et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndrome. Blood 2007, 110:3365-3373.
19. Gondek L.P., Tiu R., O'Keefe C.L., Sekeres M.A., Theil K.S., Maciejewski J.P. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008, 111:1534-1542.
20. Dunbar A.J., Gondek L.P., O'Keefe C.L., Makishima H., Rataul M.S., Szpurka H., et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 2008, 68:10349-10357.
21. Kopp P., Jaggi R., Tobler A., Borisch B., Oestreicher M., Sabacan L., et al. Clonal X-inactivation analysis of human tumors using the human androgen receptor gene (HUMARA) polymorphism: a non-radioactive and semiquantitative strategy applicable to fresh and archival tissue. Mol Cell Probes 1997, 11:217-228.
22. Vogelstein B., Fearon E.R., Hamilton S.R., Preisinger A.C., Willard H.F., Michelson A.M., et al. Clonal analysis using recombinant DNA probes from the X-chromosome. Cancer Res 1987, 47:4806-4813.
23. Willman C.L., Busque L., Griffith B.B., Favara B.E., McClain K.L., Duncan M.H., et al. Langerhans'-cell histiocytosis (Histiocytosis X)-a clonal proliferative disease. N Engl J Med 1994, 331:154-160.
24. Paquette R.L., Shah N.P., Sawyers C.L., Martinelli G., Nicoll J., et al. PHA-739358, an Aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL. Blood 2007, 110:312a.
25. Fabarius A., Haferlach C., Muller M.C., Erben P., Lahaye E., Giehl M., et al. Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. Haematologica 2007, 92:834-837.
26. Fayad L., 6Kantarjian H., O'Brien S., Seong D., Albitar M., Keating M., et al. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia 1997, 11:767-771.
27. Kharbanda S., Yuan Z.-M., Weichselbaum R., Kufe D. Determination of cell fate by c-Abl activation in the response to DNA damage. Oncogene 1998, 17:3309-3318.
28. Levav-Cohen Y., Goldberg Z., Zuckerman V., Grossman T., Haupt S., Haupt Y. C-Abl as a modulator of p53. Biochem Biophys Res Commun 2005, 331:737-749.
29. Fanta S., Sonnenberg M., Skorta I., Duyster J., Miething C., Aulitzky W.E., et al. Pharmacologic inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells. Oncogene 2008, 27:4380-4384.
30. Jasek M., Gondek L.P., Bejanyan N., Tiu R.V., Huh J., Theil K.S., et al. SNP array-based analysis of chromosome 17 reveals biallelic TP53 mutations due to uniparental disomy 17p in advanced MDS and AML with cooperating deletions of chromosomes 5 and 7. Blood. 2008, 112:875a.
31. Pekova S., Cmejla R., Smolej L., Kozak T., Spacek M., Prucha M. Identification of a novel, transactivation-defective splicing variant of p53 gene in patients with chronic lymphocytic leukemia. Leukemia Res 2008, 32:395-400.
32. Sterkers Y., Preudhomme C., Laï J.L., Demory J.L., Caulier M.T., Wattel E., et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998, 91:616-622.
33. Neri A., Fracchiolla N.S., Radaelli F., Boletini A., Ribera S., Migliorini C., et al. p53 tumour suppressor gene and RAS oncogenes: molecular analysis in the chronic and leukaemic phases of essential thrombocythaemia. Br J Haematol 1996, 93:670-673.